We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Suppressing Cancer Transcriptional Regulatory Complex Activity May Depend on Inositol Phosphate Signaling

By LabMedica International staff writers
Posted on 24 Jan 2012
A recent paper detailed the structure of a transcriptional regulatory complex, which revealed a link between inositol phosphate signaling and the regulation of histone deacetylase enzymes.

Histone deacetylase enzymes (HDACs) are emerging cancer drug targets. More...
They regulate gene expression by removing acetyl groups from lysine residues in histone tails, resulting in chromatin condensation.

Investigators at the University of Leicester (United Kingdom) described the structure of a complex between an HDAC and a corepressor, namely, human HDAC3 with the deacetylase activation domain (DAD) from the human SMRT co-repressor in the January 9, 2012, online edition of the journal Nature.

The structure revealed two remarkable features. First, the SMRT-DAD underwent a large structural rearrangement on forming the complex. Second, there was an essential inositol tetraphosphate molecule -- d-myo-inositol-(1,4,5,6)-tetrakisphosphate -- acting as an “intermolecular glue” between the two proteins.

Senior author Dr. John Schwabe, professor of biochemistry at the University of Leicester, said, “We have discovered a completely new and unexpected link between inositol phosphate signaling (in this case IP4) and the regulation of histone deacetylase enzymes, and hence transcriptional repression or gene silencing. In simple terms, we have shown that IP4 acts as a natural signaling molecule to regulate histone deacetylase enzymes, which play a key role in regulating gene expression. Apart from the considerable intellectual importance of understanding how transcription is regulated, repression complexes are important therapeutic targets for a number of cancers including several types of leukemia.”

“Our research identifies several new means to potentially target histone deacetylase enzymes therapeutically, either by using drugs to prevent IP4 binding to the enzyme or by interfering with the pathway through which the body makes IP4,” said Dr. Schwabe. “Thus, this work opens up a whole new area of research with potential for new drugs and a new approach to targeting histone deacetylase enzymes.”

Related Links:

University of Leicester





Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.